Pharma

Your Article Summary

See Latest Articles

XenoPort Reports Preliminary Results From a Safety and Tolerability Trial of Arbaclofen Placarbil in Patients With Acute Back Spasms
XenoPort, 09/09/09

XenoPort, Inc. announced preliminary results from a Phase 2 clinical trial that evaluated the safety and tolerability of arbaclofen placarbil, also known as XP19986, when administered without titration to patients with acute back spasms. All doses of AP were safe and generally well tolerated.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09

Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09

Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09

See All of Research & Development